Department of Chemical Engineering, Auburn University, 212 Ross Hall, Auburn, Alabama 36849, USA.
AAPS PharmSciTech. 2012 Dec;13(4):1396-406. doi: 10.1208/s12249-012-9866-4. Epub 2012 Oct 9.
Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO(2) to improve itraconazole dissolution. In this study, itraconazole and succinic acid were simultaneously dissolved in a liquid solvent, tetrahydrofuran, at ambient conditions. The solution was then pressurized with CO(2), which decreased the solvating power of tetrahydrofuran and caused crystallization of itraconazole-succinic acid cocrystals. The cocrystals prepared by GAS cocrystallization were compared to those produced using a traditional liquid antisolvent, n-heptane, for crystallinity, chemical structure, thermal behavior, size and surface morphology, potential clinical relevance, and stability. Powder X-ray diffraction, Fourier transform infrared spectroscopy, differential scanning calorimetry, and scanning electron microscopy analyses showed that itraconazole-succinic acid cocrystals with physical and chemical properties similar to cocrystals produced using a traditional liquid antisolvent technique can be prepared by CO(2) antisolvent cocrystallization. The dissolution profile of itraconazole was significantly enhanced through GAS cocrystallization with succinic acid, achieving over 90% dissolution in less than 2 h. The cocrystals appeared stable against thermal stress for up to 4 weeks under accelerated stability conditions, showing only moderate decreases in their degree of crystallinity but no change in their crystalline structure. This study shows the utility of an itraconazole-succinic acid cocrystal for improving itraconazole bioavailability while also demonstrating the potential for CO(2) to replace traditional liquid antisolvents in cocrystal preparation, thus making cocrystal production more environmentally benign and scale-up more feasible.
伊曲康唑的共晶,一种生物利用度差的抗真菌药物,与顺丁二酸,一种水溶性二羧酸,通过气体抗溶剂(GAS)共结晶形成,以提高伊曲康唑的溶解度。在这项研究中,伊曲康唑和丁二酸同时溶解在四氢呋喃等液体溶剂中,在环境条件下。然后用 CO2 加压,降低四氢呋喃的溶解能力,导致伊曲康唑-顺丁二酸共晶结晶。用 GAS 共结晶制备的共晶与使用传统液体抗溶剂,正庚烷,进行结晶度、化学结构、热行为、尺寸和表面形态、潜在临床相关性和稳定性的比较。粉末 X 射线衍射、傅里叶变换红外光谱、差示扫描量热法和扫描电子显微镜分析表明,通过 CO2 抗溶剂共结晶可以制备出具有与使用传统液体抗溶剂技术生产的共晶相似的物理和化学性质的伊曲康唑-顺丁二酸共晶。通过与顺丁二酸的 GAS 共结晶,伊曲康唑的溶解性能显著提高,不到 2 小时即可达到 90%以上的溶解。共晶在加速稳定性条件下,在长达 4 周的时间内对热应力表现出稳定,仅显示出适度降低结晶度,但结晶结构没有变化。这项研究表明,伊曲康唑-顺丁二酸共晶可用于提高伊曲康唑的生物利用度,同时还表明 CO2 有可能替代传统的液体抗溶剂用于共晶制备,从而使共晶生产更环保,规模更大。